Department of Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Division of Gynecologic Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Gynecol Oncol. 2021 Sep;162(3):751-755. doi: 10.1016/j.ygyno.2021.06.011. Epub 2021 Jun 17.
Minimally invasive surgery (MIS) is increasingly utilized for gynecologic cancers. While incidence of venous thromboembolism (VTE) after MIS is low, some guidelines recommend extended chemoprophylaxis for these patients undergoing MIS. Our objectives were to determine incidence of postoperative VTE in patients undergoing MIS, evaluate differences in the incidence by MIS modality and assess the need for extended chemoprophylaxis.
We conducted a retrospective cohort study including all patients undergoing MIS (robot-assisted, multi-port laparoscopy, single-port laparoscopy) for gynecologic cancers between January 2014 and December 2018 at our institution. Demographic and perioperative variables were collected. Patients <18 years, with benign pathology, or on preoperative anticoagulation were excluded. Chi-square, Fisher's exact test, and one-way ANOVA were performed to determine risk factors related to VTE occurrence.
We identified 806 patients who underwent MIS with median age 61. Most had Stage I disease (81.5%) and uterine cancer (81.5%). Five VTE events occurred within 90 days following surgery (0.6%). Incidence of 90-day VTE did not differ between MIS modalities (p = 0.6). Patients with longer OR times (p = 0.004) were more likely to experience VTE. Age, smoking status, BMI, type of cancer and stage were not significant risk factors for VTE.
The incidence of postoperative VTE in patients with gynecologic cancers undergoing MIS is low and does not appear to differ by MIS modality. Given the very low incidence of postoperative VTE, extended chemoprophylaxis is unlikely to benefit patients with gynecologic malignancies undergoing MIS procedures.
微创手术(MIS)越来越多地用于妇科癌症。虽然 MIS 后静脉血栓栓塞(VTE)的发生率较低,但一些指南建议对接受 MIS 的这些患者进行延长化学预防。我们的目的是确定接受 MIS 的患者术后 VTE 的发生率,评估 MIS 方式对发病率的影响,并评估延长化学预防的必要性。
我们进行了一项回顾性队列研究,纳入了 2014 年 1 月至 2018 年 12 月期间在我们机构接受 MIS(机器人辅助、多孔腹腔镜、单孔腹腔镜)治疗妇科癌症的所有患者。收集了人口统计学和围手术期变量。排除年龄<18 岁、良性病理或术前抗凝的患者。采用卡方检验、Fisher 确切检验和单向方差分析来确定与 VTE 发生相关的危险因素。
我们确定了 806 例接受 MIS 的患者,中位年龄为 61 岁。大多数患者为 I 期疾病(81.5%)和子宫癌(81.5%)。术后 90 天内发生 5 例 VTE 事件(0.6%)。不同 MIS 方式之间 90 天 VTE 的发生率无差异(p = 0.6)。手术时间较长的患者(p = 0.004)更有可能发生 VTE。年龄、吸烟状况、BMI、癌症类型和分期不是 VTE 的显著危险因素。
接受妇科癌症 MIS 的患者术后 VTE 的发生率较低,且似乎与 MIS 方式无关。鉴于术后 VTE 的发生率非常低,延长化学预防不太可能使接受妇科恶性肿瘤 MIS 手术的患者受益。